Deal Snapshot: Roche is finally returning the rights to two failed Alzheimer’s candidates. But why now?
Who: Roche Holding AG/AC Immune SA
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.
